News

May 26, 2017

SIR-Spheres Radiation Therapy Increases Chance Liver Cancer Can Be Operated on, Study Reports

News

Those with liver cancer that has spread from the colon have a better chance of surgical removal of their liver tumors after treatment with SIR-Spheres radiation microspheres, according to an ... Read more

May 25, 2017

Change in Intestinal Fungus Mix May Contribute to Alcoholic Liver Disease, Study Reports

Alcoholic liver disease, News

Alcohol alters the intestines’ fungus mix, and the imbalance may contribute to the development and progression of alcoholic liver disease (ALD), a study reports. Researchers said the findings suggest that ... Read more

May 24, 2017

Organovo’s 3D Bioprinted Tissue Transplants Improve Mice’s Liver Disease

News

Transplanting 3D bioprinted liver tissue into diseased livers improves liver health in mice, Organovo Holdings revealed. The finding suggests that doctors could use 3D bioprinted human liver tissue to correct inborn ... Read more

May 23, 2017May 23, 2017

Intercept Receives NORD Innovation Award for Ocaliva Therapy to Treat Rare Liver Disease

News

The National Organization for Rare Disorders (NORD) gave its 2017 Industry Innovation Award to Intercept Pharmaceuticals for the company’s primary biliary cholangitis (PBC) drug Ocaliva (obeticholic acid). PBC, a rare, autoimmune cholestatic ... Read more

May 22, 2017May 22, 2017

Albireo Plans Phase 3 Trial of A4250 to Treat Children with Life-threatening Liver Disease

Cholestasis, News

Children with progressive familial intrahepatic cholestasis will be able to take part in a Phase 3 clinical trial of A4250’s ability to combat the rare genetic disorder, according to its maker, ... Read more

May 19, 2017May 19, 2017

Blocking 2 Types of Immune Cells Seen to Prevent NASH in Mice, Raising Hope of Treatment

News

Nonalcoholic steatohepatitis, or NASH, might be prevented by treatments able to target certain immune cells, according to a recent study in mice which demonstrated that the condition has an inflammatory basis. Researchers discovered ... Read more

May 18, 2017May 18, 2017

Albireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases

Cholestasis, News, Non-alcoholic steatohepatitis

Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Boston-based Albireo has reported promising preclinical ... Read more

May 17, 2017May 17, 2017

Monkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis

News, Non-alcoholic steatohepatitis

Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in monkeys, according to a 12-month non-human primate toxicology ... Read more

May 16, 2017May 16, 2017

New Data Highlights Advantages of Accuray’s CyberKnife for Treating Liver Metastasis

News

Researchers presented more than 50 studies highlighting the benefits of Accuray’s CyberKnife System at the 36th Annual European Society for Radiotherapy and Oncology (ESTRO) Meeting in Vienna. One study in ... Read more

May 15, 2017

Early Study to Test Bioelectronic Treatment for NASH Inflammation

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced. This is the first of multiple ... Read more